AbCellera Biologics (ABCL) Accumulated Expenses (2022 - 2026)
AbCellera Biologics' (ABCL) quarterly Accumulated Expenses came in at $39.6 million in Q1 2026, down 17.33% YoY from $47.8 million in Q1 2025, and down 22.11% on a QoQ basis from $50.8 million in Q4 2025.
AbCellera Biologics (ABCL) Accumulated Expenses (2022 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 5 years of Accumulated Expenses data on file, last reported at $39.6 million in Q1 2026.
- Quarterly Accumulated Expenses fell 17.33% year-over-year to $39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.6 million (down 17.33% YoY) and the FY2025 annual result came in at $50.8 million, down 7.68% from the prior year.
- Accumulated Expenses declined to $39.6 million in Q1 2026, from $50.8 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $55.0 million in Q4 2024 to a low of $39.6 million in Q1 2026.
- A 5-year average of $49.0 million and a median of $50.1 million in 2025 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses rose 13.93% — and 2026, when it slipped 17.33%.
- Tracing ABCL's Accumulated Expenses over 5 years: stood at $52.5 million in 2022, then slipped by 5.56% to $49.6 million in 2023, then increased by 10.94% to $55.0 million in 2024, then fell by 7.68% to $50.8 million in 2025, then decreased by 22.11% to $39.6 million in 2026.
- The last three Accumulated Expenses figures came in at $39.6 million (Q1 2026), $50.8 million (Q4 2025), and $53.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.48 Mn |
| Mar 31, 2026 | 39.55 Mn |
| Dec 31, 2025 | 50.78 Mn |
| Sep 30, 2025 | 53.12 Mn |
| Jun 30, 2025 | 50.07 Mn |
| Mar 31, 2025 | 47.84 Mn |
| Dec 31, 2024 | 55.00 Mn |
| Sep 30, 2024 | 53.77 Mn |
| Jun 30, 2024 | 43.95 Mn |
| Mar 31, 2024 | 42.89 Mn |
| Dec 31, 2023 | 49.58 Mn |
| Dec 31, 2022 | 52.50 Mn |